Frontlight ResearchEarly access
Active, not recruitingNo phase
the Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration
Key facts
- Who runs it
- Lifetech Scientific (Shenzhen) Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 120 people, planned
- Started
- 25 Jul 2021
- Expected to end
- 30 Mar 2028
- Type of study
- Interventional
- Treatments tested
- the Aorta Arch Stent Graft System combined with the Endovascular Needle System
- Record updated
- 23 July 2024
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- 18 years old ≤age≤80 years old, no gender limitation
- Diagnosis of aortic dissection and reconstruction of the left subclavian artery
- The main branches and branches of the aortic arch at the lesion site have sufficient anatomical basis:; The diameter range of the near-end anchoring zone of the main body of the fixed mechanism: 21-46mm; The length of the anchor zone near the principal part of the tunnel is ≥10mm; The length of the anchor zone of the branching vessel of the convex target is ≥15mm; The diameter range of the distal anchoring zone of the target branching vessel is 5-18mm
- The patient has adequate surgical access vessels
- Patients who understand the purpose of the study, voluntarily participate in and sign informed consent, and are willing to follow up
Who cannot take part
- The patient has been implanted or planned to be implanted with left ventricular auxiliary pump, interventional valve and other instruments, or is planning to undergo coronary intervention surgery, and aortic dissection is expected to affect the function of such instruments or such instruments will affect the operation of aortic dissection
- Patients with a history of cerebral infarction or myocardial infarction within 3 months before surgery
- The patient had a history of cardiac surgery (congenital heart disease surgery, heart valve surgery, coronary heart disease surgery, thoracic aortic surgery, etc.), which would affect the implementation of this TEVAR surgery
- Marfan syndrome and other connective tissue diseases, arteritis
- Patients with a history of allergy to contrast agents, anesthetics, antiplatelet drugs, anticoagulants, nickel peptide alloys, and polytetrafluoroethylene materials
- Patients with active bleeding and coagulopathy
- Patients with end-stage diseases with a life expectancy of less than one year
- Abnormal renal function: patients with preoperative creatinine > 2.5 times the normal upper limit value
- Abnormal liver function: patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the normal upper limit value, or patients with serum total bilirubin (STB) > 2 times the normal upper limit value
- The patient is pregnant or breastfeeding
- Patients with severe hematoma on the aortic wall in the proximal anchoring area of the stent
- patients with poor compliance considered by the investigator
- Patients participating in other clinical trials at the same time
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A prospective, multi-center, single-group target value method to evaluate the safety and effectiveness of the Aorta Arch Stent Graft System combined with the Endovascular Needle System in situ fenestration technology in the treatment of aortic dissection involving the aortic arch
The group in the trial
- aortic dissection involving the aortic archTreatment being tested
Aortic dissection involving the aortic arch was diagnosed in patients requiring revascularization of the aortic arch and its branches
Treatment: the Aorta Arch Stent Graft System combined with the Endovascular Needle System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration Technology in the Treatment of Aortic Dissection Involving the Aortic Arch
- Publications
- Early Results of a Single-Center Prospective Clinical Trial: In Situ Fenestration System for Aortic Dissection.Vascular and endovascular surgery, 2025
- Record updated
- 23 July 2024